Detalles de la búsqueda
1.
Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict).
Breast Cancer Res Treat
; 191(2): 327-333, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34783927
2.
Endothelial-to-Mesenchymal Transition as Underlying Mechanism for the Formation of Double-Chambered Right Ventricle.
Pediatr Cardiol
; 43(5): 1084-1093, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35084525
3.
PARP-1 expression as a prognostic factor in Desmoid-type fibromatosis.
Ann Diagn Pathol
; 44: 151442, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31855806
4.
Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years.
Mod Pathol
; 31(4): 607-615, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29271415
5.
An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.
Clin Cancer Res
; 2024 Jun 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38837894
6.
Effectiveness of Immune Checkpoint Inhibition vs Chemotherapy in Combination With Radiation Therapy Among Patients With Non-Small Cell Lung Cancer and Brain Metastasis Undergoing Neurosurgical Resection.
JAMA Netw Open
; 5(4): e229553, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35486401
7.
APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma.
Histol Histopathol
; 34(4): 405-417, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30289149
8.
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Oncotarget
; 7(2): 1486-99, 2016 Jan 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-26625204
9.
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
J Clin Oncol
; 32(29): 3212-20, 2014 Oct 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-25199759
Resultados
1 -
9
de 9
1
Próxima >
>>